and they have a smaller CO 2 -emission footprint than transition-metal oxides 2 . However, batteries whose electrodes contain organic materials have short cycle lives (the number of charge-discharge cycles a battery can undergo while retaining at least 80% of its initial capa city) and low power capabilities, which make charging slow. Other intrinsic problems of organic electrodes include the fact that they dissolve in electrolytes (the ionic media that allow charge flow in batteries), are chemically unstable when in a charged state and have poor electrical conductivity 6, 7 . Kolek et al. report an organic electrode material called poly(3-vinyl-N-methylphenothiazine) (PVMPT; Fig. 1 ) that might overcome these problems. The design of this polymer stemmed from the authors' idea that the stability of organic materials can be remarkably improved by designing molecular structures that generate strong intermolecular forces, particularly when in a charge-storing state. In typical organic batteries, electrons and guest ions (such as lithium ions in lithium-ion batteries) are passed between electrodes during charge and discharge; the electroactive organic materials store the extra charge that accumulates. However, the additional charge tends to localize to certain parts (functional groups) of the organic molecule. In high-capacity batteries that involve the transfer of great numbers of electrons, this charge localization causes free radicals to form, making the molecule unstable and vulnerable to side reactions 8 . But in PVMPT, a strong intermolecular force (known as a π-π interaction) forms between the polymer's stacked aromatic rings upon the introduction of extra charge. This force effectively delocalizes the accumulated charges, stabilizing the whole molecule and preventing unwanted side reactions. More over, the electrical conductivity of the polymer is enhanced by this intermolecular association, leading to faster battery charging and discharging.
Remarkably, Kolek and colleagues found that a PVMPT-containing battery cell could operate stably for 10,000 charge-discharge cycles with quick battery charging (148 seconds per charge). This cycle life is one of the longest reported among batteries that use organic electrodes -which typically have lives of fewer than 500 cycles 9 -and even exceeds the cycle lives of conventional transition-metal-oxide electrodes (about 1,000 cycles 5, 10 ). The polymer also enables an operation voltage of 3.55 volts, which is comparable with that of conventional electrodes 5 , but higher than that of typical organic electrodes, which produce voltages 7 of about 1-3 V. The relatively high voltage of PVMPT implies that a large amount of energy can be stored for a given amount of charge.
But PVMPT is not without faults. Its charge capacity is only 50 milliamp-hours per gram -less than one-third of that of conventionally used transition-metal oxides 5, 10 -meaning that batteries incorporating the polymer would be much heavier and larger than those made using the oxides. And even though the conductivity of PVMPT is improved by introducing strong intermolecular forces, it is still less than one-hundredth of that of conventional transition-metal oxides 1, 11, 12 . A large amount of a conducting agent, such as carbon, would therefore need to be added to PVMPT for practical applications, further reducing the charge capacity. Nevertheless, the chemical diversity of organic materials is expected to provide great opportunities in the search for a more optimal high-capacity polymer electrode.
Kolek H aematopoietic stem cells in the embryo can give rise to all lineages of blood cell, but not all blood cells derive from haematopoietic stem cells (HSCs). For instance, erythro-myeloid progenitors (EMPs) emerge in an embryonic structure called the yolk sac before HSCs exist, and give rise to diverse lineages of blood cell that are crucial for survival 1 . In addition to their role in development, EMPs give rise to a long-lived population of adult immune cells of the myeloid lineage, called EMP-derived tissue macrophages [2] [3] [4] . These cells are found in many adult tissues, including the brain, heart and skin, and can coexist with HSC-derived macrophages -a fact that has led some researchers to speculate that these two embryonic cell populations have different roles in adult disease 5, 6 . On page 389, Mass et al. 7 provide definitive support for this hypothesis.
Histiocytoses are a group of diseases characterized by an abundance of macrophages or immune cells called dendritic cells 8 . They can affect diverse organs, including the bone, skin and spleen. Central nervous system (CNS) involvement is rare, but has a poor prognosis 8 . A common cause of histiocytoses 8 is a single amino-acid substitution in the gene BRAF. The resulting mutation (dubbed BRAF V600E ) causes hyperactive RAS-pathway signalling that leads to excessive proliferation of cells. Interestingly, although this mutation is found in hairy cell leukaemia (a cancer of white blood cells called B cells), it has not been detected in myeloid leukaemias 9, 10 , which involve myeloid cells. The differing frequency of BRAF V600E mutations in histiocytoses and myeloid leukaemias suggests that, even though both these blood-cell disorders involve myeloid cells, they might have To investigate the possibility that histiocytoses are caused by EMP-derived cells, Mass et al. generated genetically engineered mice in which embryonic EMPs alone harboured the Braf V600E mutation. By monitoring Braf V600E -expressing cells using a fluorescent marker, the authors confirmed that the mutation was not present in HSCs. Mice with Braf V600E -expressing EMPs showed no evidence of disease prenatally or immediately after birth. Nevertheless, mutant EMPs gave rise to expanded populations of macrophagesincluding those in the CNS, known as microglia -indicative of a histiocytosis. Mutant microglia in one-month-old mice proliferated more and underwent programmed cell death less often than did EMP-derived microglia in control animals. The mutant mice subsequently developed progressive neurological impairment, characterized by muscle weakness, impaired motor coordination, loss of reflexes and, ultimately, limb paralysis.
Mass et al. observed that mutant microglia had a rounded shape indicative of activation. They found hallmarks of neurodegeneration in nearby cells: deposition of amyloid precursor protein; loss of neurons and marked damage to the protective myelin sheath around them; and an increase in the numbers of neuron-supporting astrocyte cells (Fig. 1) . These findings suggest that factors secreted from activated mutant microglia were driving disease. Indeed, the authors performed a gene-expression analysis that confirmed the upregulation of several markers of neurodegeneration in the CNS of mutant mice. These include pro-inflammatory mediators such as interleukin-1β (IL-1β) and IL-17α, growth factors that signal through the RAS pathway, and proteins associated with the extracellular matrix around cells.
The researchers are the first to prove that embryonic mutations in EMPs can cause neurodegenerative disease after birth in mice. Their conclusions emphasize that developmental origins should be considered when studying disorders caused by blood cells. Furthermore, the authors highlight the different responses of distinct blood-cell lineages to cancer-causing mutations. Whereas Braf V600E expression in EMPs caused neurodegeneration, the same mutation expressed in HSCs in mice caused prenatal lethality or myeloidcell tumours in diverse tissues, including the spleen, lungs and bone marrow. This finding suggests that the EMP lineage might be resistant to cancerous transformation. Further work will be needed to identify the properties of EMPs that confer this resistance -knowledge that could potentially be used to evoke similar protective signals in HSC-derived blood cells.
A crucial next step in understanding how EMP-derived cells cause neurodegeneration will be to determine the precise contribution of aberrant developmental cues to this process. For instance, would postnatal Braf V600E mutations in microglia also result in progressive ataxia and limb weakness, or are these symptoms dependent on the prenatal seeding of the CNS with mutant microglia? Clarifying the developmental stage at which microglia are susceptible to the effects of mutations will refine our understanding of disease pathogenesis and help to identify potential therapeutic windows for intervention. Mass and colleagues' findings could help in the diagnosis of neurodegenerative disorders caused by EMPs. They identified more than 8,000 genes that were differentially expressed between mutant and control microglia. Further analysis of this gene set might enable the identification of a unique geneexpression signature for embryonically derived neurodegenerative disorders. The authors also demonstrate that, in addition to causing defects in the CNS of their mice, mutant EMPs gave rise to abnormal macrophages in the spleen, liver and lung. This suggests that it might be possible to collect macrophage samples from more-easily-accessible, non-CNS tissues to look for biomarkers when diagnosing microglia-related disease.
EMPs are a remarkable and under-explored contributor to neurodegenerative disorders. The challenge ahead will be to translate this discovery into treatments. Mass and colleagues' findings hint at two possible strategies. First, targeted therapy against key signalling molecules might delay the onset of symptoms. The authors demonstrated that blocking hyperactive RAS signalling using a BRAF V600E inhibitor could delay the onset of neurological defects in their mutant mice. In addition, they analysed several CNS samples from patients who had histiocytoses, and found notable similarities with their model mice, including microglial activation, hyperactive RAS signalling and overexpression of pro-inflammatory signalling molecules, including IL-1β and IL-17α. In support of this strategy, some patients with histiocytic CNS diseases have shown promising responses to BRAF V600E inhibition 11, 12 . It is to be hoped that future controlled studies will assess the efficacy of this approach and identify those patients who might benefit.
A second and more intriguing strategy would be to further explore differences between EMPs and HSCs that express BRAF V600E . This approach would draw on the depth of our understanding of blood-cell development to identify molecular targets that are specific to EMPs. Such knowledge could lead to highly specific, HSC-sparing therapies whose mechanism of action is restricted to EMPs or microglia. ■ A dditive manufacturing of metals, also known as metal 3D printing, was not long ago seen only as a means of making prototypes of mechanical components for industry. But it is now considered to be a potentially transformative manufacturing process for many sectors. This change has been driven by diverse factors 1 , such as the complex geometries that can be achieved, the relatively low number of parts required for components made in this way, and the fact that manufacturing timescales are much shorter than those of conventional manufacturing methods. However, the limited range of industrially useful alloys that can be processed in the additive manufacturing of metals is a barrier to its wide adoption. On page 365, Martin et al. 2 report an approach that expands the range of metallic materials that can be used, taking lessons from a much older manufacturing process -casting.
Metal additive manufacturing (AM) often involves the deposition of layers of an alloy feedstock in the form of powders or wires, which are melted together by a rapidly moving heat source to form a solid mass. Successive layers are built up to produce a 3D component. The rate of solidification is often an order of magnitude higher than that seen during conventional casting techniques, and the process of building up layers causes non-uniform cooling, which, in turn, leads to large temperature gradients or thermal stresses in the alloy.
The picture is further complicated by the solidification processes that occur in alloys used for engineering applications, such as high-strength aluminium and nickel super alloys. These materials tend to have relatively wide temperature ranges over which liquid and solid phases can coexist, and often solidify as either columnar grains or dendrites (multi-branched crystal formations) under the conditions imposed by AM. As solidification proceeds, the liquid content of the alloy decreases, and the residual liquid becomes confined to channels between the cells or dendrites, where it forms a film. Localized contraction of the solid can then cause cavities to form in the liquid film; if these cavities propagate, they generate cracks known as hot tears 3 . The resulting material can therefore contain both a columnar microstructure and numerous cracks -neither of which would be acceptable for engineering applications.
Martin et al. now suggest that a possible way of suppressing hot tearing in AM would be to change the dominant solidification mode from directional columnar growth to nondirectional growth that produces 'equiaxed' grains -which have roughly equal width, length and height. However, once again, the local solidification conditions that occur during AM work against this: steep thermal gradients are generated, which suppress the 
